News | February 17, 2015

Study compares baseline characteristics of participants, eligible non-participants for low dose computed tomography screening

CT systems, computed tomography, lung cancer, study, screening, Europe

February 17, 2015 — Results of the NELSON lung cancer screening trial using low dose computed tomography (LDCT) can be used to predict the effect of population-based screening on the Dutch population. Researchers say the study results — which were published in the Journal of Thoracic Oncology — can be used even though there were slight differences in baseline characteristics of participants in the control arm versus eligible non-participants.

In the United States, the National Lung Screening Trial (NLST) showed that lung cancer screening with LDCT can reduce lung cancer mortality by 20 percent compared to chest X-ray for a high-risk population defined as current or former smokers with at least a 30 pack-year history and an age of 55-74 years. In Europe, the ongoing Dutch-Belgian lung cancer screening trial (NELSON) investigated whether screening with LDCT can reduce lung cancer mortality by at least 25 percent compared to no screening at 10 years of follow-up for individuals aged 50-75 years with a smoking history of 15 cigarettes per day for 25 years or 10 cigarettes for 30 years, and were still smoking or had quit 10 years ago. It is important when interpreting the results of screening studies to know whether study participants are representative of the target population, since there may be selection bias in the volunteers who are willing to participate in screening programs.

In the NELSON trial individuals at high risk for lung cancer were identified by sending a health questionnaire to 606,409 persons aged 50-74. Of those that responded, 30,051 eligible subjects received an invitation to participate with 15,822 accepting and randomized to either LDCT (N=7,915) or control (N=7,907). The remaining individuals were defined as eligible non-responders (non-participants), and in this sub-study of the NELSON trial the baseline characteristics and mortality profiles of eligible non-participants (N=13,670) were compared to the control arm (N=7,453).

The results show that the control participants of the NELSON trial were statistically younger, had better self-reported health, were more physically active, higher educated, and more often former smokers compared to eligible non-participants, although the actual numerical differences were minimal. Eligible non-participants had a higher all-cause mortality rate and mortality due to cardiovascular, respiratory, and non-cancerous diseases. However, the relative proportion of subjects that died due to all types of cancer was higher among participants.

The authors noted that "so far no large lung screening trial using LDCT has studied the differences in baseline characteristics and potential effect on mortality profiles between participants and eligible non-participants. While the distribution of participant characteristics in the NELSON study suggest that the study population is somewhat younger, healthier (e.g. more physically active, less current smokers), higher educated and has a slightly different mortality rate profiles, these differences are modest and therefore it seems unlikely that these differences will influence the generalizability of the main results of the NELSON trial to the target population."

For more information: www.iaslc.org


Related Content

News | Artificial Intelligence

Sept. 13, 2024 — Bayer Calantic Digital Solutions has announced the availability of a new eBook that addresses how ...

Time September 12, 2024
arrow
News | Computed Tomography (CT)

At the annual AHRA (American Healthcare Radiology Administrators) conference in Orlando, Florida, Bayer announced an ...

Time August 09, 2024
arrow
Videos | Radiology Business

Find actionable insights to achieve sustainability and savings in radiology in this newest of ITN’s “One on One” video ...

Time July 30, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
News | Radiopharmaceuticals and Tracers

July 24, 2024 — Telix Pharmaceuticals Limited announced that the United States (U.S.) Food and Drug Administration (FDA) ...

Time July 24, 2024
arrow
News | RSNA

July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 22, 2024 — Healthcare artificial intelligence (AI) systems provider, Qure.ai, has announced its receipt of a Class ...

Time July 22, 2024
arrow
News | PET-CT

July 16, 2024 — A new research paper was published in Oncotarget's Volume 15 on June 20, 2024, titled, “Comparison of ...

Time July 16, 2024
arrow
News | Prostate Cancer

July 11, 2024 — GE HealthCare’s MIM Software, a global provider of medical imaging analysis and artificial intelligence ...

Time July 11, 2024
arrow
News | Radiation Therapy

July 3, 2024 — Results from a new study led by researchers at The University of Texas MD Anderson Cancer Center support ...

Time July 03, 2024
arrow
Subscribe Now